HK1030338A1 - Treatment of schizophrenia with ampakines and neuroleptics - Google Patents

Treatment of schizophrenia with ampakines and neuroleptics

Info

Publication number
HK1030338A1
HK1030338A1 HK01101109A HK01101109A HK1030338A1 HK 1030338 A1 HK1030338 A1 HK 1030338A1 HK 01101109 A HK01101109 A HK 01101109A HK 01101109 A HK01101109 A HK 01101109A HK 1030338 A1 HK1030338 A1 HK 1030338A1
Authority
HK
Hong Kong
Prior art keywords
schizophrenia
treatment
ampakines
neuroleptics
relates
Prior art date
Application number
HK01101109A
Other languages
English (en)
Inventor
Steven A Johnson
Gary A Gers
Gary S Lynch
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1030338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of HK1030338A1 publication Critical patent/HK1030338A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK01101109A 1997-10-27 2001-02-15 Treatment of schizophrenia with ampakines and neuroleptics HK1030338A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (1)

Publication Number Publication Date
HK1030338A1 true HK1030338A1 (en) 2001-05-04

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101109A HK1030338A1 (en) 1997-10-27 2001-02-15 Treatment of schizophrenia with ampakines and neuroleptics

Country Status (15)

Country Link
US (1) US6166008A (el)
EP (1) EP1026950B1 (el)
JP (1) JP2001520978A (el)
CN (1) CN1281335A (el)
AT (1) ATE317226T1 (el)
AU (1) AU745641B2 (el)
BR (1) BR9814106A (el)
CA (1) CA2306817A1 (el)
CY (1) CY1105557T1 (el)
DE (1) DE69833451T2 (el)
DK (1) DK1026950T3 (el)
ES (1) ES2258825T3 (el)
HK (1) HK1030338A1 (el)
PT (1) PT1026950E (el)
WO (1) WO1999021422A1 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174851T3 (es) 1992-07-24 2002-11-16 Univ California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
EP1423103A4 (en) * 2001-08-10 2008-03-19 Univ Rockefeller COMPOSITIONS AND METHOD FOR MODULATING DARPP-32 PHOSPHORYLATION
BRPI0406736A (pt) * 2003-01-13 2005-12-20 Cortex Pharma Inc Método de tratar declìnico cognitivo devido à privação de sono e estresse
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7282519B2 (en) 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
CA2571243A1 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008531579A (ja) * 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
SI2332909T1 (sl) 2005-04-13 2015-01-30 Astex Therapeutics Limited Derivati hidroksibenzamida in njih uporaba kot inhibitorji hsp90
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
EP1960373A2 (en) * 2005-11-22 2008-08-27 NeuroSearch A/S Novel quinoxaline derivatives and their medical use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
RU2010106975A (ru) 2007-08-10 2011-09-20 Кортекс Фармасьютикалз, Инк. (Us) Бициклические амиды для усиления глутаматергических синаптических ответов
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
SG173168A1 (en) * 2009-02-02 2011-08-29 Cortex Pharma Inc Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
JP2015520191A (ja) 2012-06-05 2015-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ncamペプチド模倣体を用いた精神障害またはその症状を治療するための方法
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
ES2258825T3 (es) 2006-09-01
DK1026950T3 (da) 2006-06-26
DE69833451D1 (de) 2006-04-20
CY1105557T1 (el) 2010-07-28
US6166008A (en) 2000-12-26
ATE317226T1 (de) 2006-02-15
CA2306817A1 (en) 1999-05-06
PT1026950E (pt) 2006-06-30
EP1026950A4 (en) 2004-07-07
AU1365899A (en) 1999-05-17
AU745641B2 (en) 2002-03-28
BR9814106A (pt) 2000-10-03
WO1999021422A1 (en) 1999-05-06
EP1026950B1 (en) 2006-02-08
EP1026950A1 (en) 2000-08-16
CN1281335A (zh) 2001-01-24
DE69833451T2 (de) 2006-09-28
JP2001520978A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
HK1030338A1 (en) Treatment of schizophrenia with ampakines and neuroleptics
DE69429524T2 (de) Aminocyclohexylester und ihre anwendung
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
BG100830A (en) Naphthylamides as central nervous system agents
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
DE69813898D1 (de) Substituierte porphyrinen
IL134089A0 (en) 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
GB0216865D0 (en) Targetted agents for nerve regeneration
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TW200503717A (en) Substituted 1,4-pyrazine derivatives
WO2001007431A3 (en) Benzothiophene derivatives
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
DE60029119D1 (de) Disulfidkonjugierte zellgifte und verfahren zur ihrer herstellung und verwendung
TR200000916T2 (tr) İkameli piperidin türevleri.
CA2180155A1 (en) Naphthylamides as central nervous system agents

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF : [73] CORTEX PHARMACEUTICALS, INC - 15241 BARRANCA PARKWAY - IRVINE, CA 92718 - UNITED STATES/UNITED STATES OF AMERICA - THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - 12TH FLOOR, 1111 FRANKLIN STREET - OAKLAND - CALIFORNIA 94607-5200 - UNITED STATES/UNITED STATES OF AMERICA - DATED 15.9.2006

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131026